32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. (September 2015) - Segelov, E.; Thavaneswaran, S.; Waring, P.; Desai, J.; Mann, K.; Elez, E.; Chantrill, L.; Pavlakis, N.; Nott, L.; Underhill, C.; Khasraw, M.; Wasan, H.; et al.